Financial News
Pfizer/BioNTech COVID-19 booster 95.6% effective against disease: study
October 21, 2021 at 09:46 AM EDT
A 30-microgram booster dose showed a relative vaccine efficacy of 95.6% in individuals who had previously received the Pfizer/BioNTech primary two-dose series, the companies announced.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
